Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

Trial Identifier: 213351
Sponsor: Tesaro
Start Date: October 2017
Primary Completion Date: February 2020
Study Completion Date: December 2024
Condition: Cancer - Other; Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
United States, AZ Scottsdale, AZ, United States, 85258
United States, CA Encinitas, CA, United States, 92024
United States, CA San Marcos, CA, United States, 92069
United States, FL Sarasota, FL, United States, 34232
United States, OH Canton, OH, United States, 44718
United States, OH Cleveland, OH, United States, 44106
United States, TN Nashville, TN, United States, 37203
United States, TX Houston, TX, United States, 77030